Forest gaining 'relevant' GI position with Furiex buy

Just because Actavis will pay $25bn to acquire Forest Laboratories, that doesn't mean New York-based Forest's own acquisitive streak is coming to an end, as evidenced by the company's latest investment – at least $1.1bn to buy Furiex Pharmaceuticals.